Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine.

摘要: We investigated the possible pharmacokinetic interactions of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ten stage tumors were treated (1500 mg/m 2 ) as a 30-min intravenous infusion on days 1 8, followed by (130 4-h infusion, day 8 every 21 days. Pharmacokinetic data for 24 h after dosing obtained both (gemcitabine without coadministration) oxaliplatin) during first cycle treatment. Gemcitabine levels plasma quantified using reverse-phase high-performance liquid chromatography assay ultraviolet detection, total ultrafiltrated platinum flameless atomic absorption spectrophotometry deuterium correction. All parameters seemed to be unchanged when coadministered (day 8) compared given single agent 1). The mean (maximum) concentration was 13.57 (±7.42) 10.23 (±5.21) mg/l, respectively (P=0.28), half-life 0.32 0.44 h, (P=0.40). Similarly, P-values AUC 0-24 observed clearance 0.61 0.30, respectively. Plasma free agreement other published data. disposition appeared unaffected coadministration because no significant changes pharmacokinetics between observed.